There is no FDA exosome approval for any product. So what can a clinic still put on its website? Less than most owners hope, and more than nothing. This post covers what a clinic can publish about exosomes. The short answer is education only. And one consult line can turn that education into an offer.
TLDR: No exosome product is FDA approved for any use, and the FDA treats exosomes used to treat disease as drugs and biological products. With no FDA exosome approval, the product’s status is the core exposure. The wording comes second. A clinic can publish biology and status. It cannot add a procedure, a price, a booking button or a consult invite. Each one turns education into an offer. Read on to see where that line sits.
Important Note
This article is for educational purposes only and does not constitute legal, medical, or regulatory advice. Marketing strategies discussed should be reviewed by qualified legal counsel before implementation, particularly regarding FDA, FTC, and state-specific advertising regulations. Regen Portal is a marketing and consulting company, not a law firm.
Clinic owners ask me two things about exosomes. Can we offer them? And if we do, what can we say? The first question belongs to your counsel. The second one I can help with, and the answer is shorter than most people expect.
A lot of the exosome copy I see was not written by the clinic. It came from a supplier’s handout, a conference slide or a competitor’s page. Once it sits on your site, it is your claim.
So let’s walk through what the FDA has said and what that leaves a clinic to publish. Then we’ll find where education stops and an offer starts.
What the FDA Has Said About Exosome Products
The FDA has said the same two things since 2019. No exosome product is FDA approved for any use, and the FDA treats exosomes used to treat disease as drugs and biological products. Those products need premarket review and approval before anyone can sell them as a treatment.
The FDA’s public safety notification on exosome products came out in December 2019. It says exosomes used to treat diseases and conditions in people are subject to premarket review and approval. The agency’s consumer alert on regenerative medicine products says it again: there are currently no FDA-approved exosome products.
The letters have kept coming. In 2025, the FDA sent several warning letters over unapproved exosome products sold with treatment claims. In August 2026, a letter to a cord product supplier listed its exosome products as unlicensed biologics. On October 13, 2026, the FDA’s biologics center warned an IV hydration brand. It sold exosome IV packages in soft, hedged words. That record is current as of November 3, 2026. You can search it on the FDA warning letter page.
What this means for your practice: This is not a new position, and it is not a quiet one. Plan your exosome content around it, not around what a supplier tells you.
Why the Product’s Status Is the Core Exposure
The exposure starts with the product, not only with the words around it. In the FDA’s eyes, an exosome product sold to treat a condition is an unapproved drug. It is also an unlicensed biologic. Careful wording does not change that.
You may hear that exosomes are fine to offer as long as the marketing is careful. I would not lean on that. Whether a clinic should offer one at all is a legal call. That call belongs to your counsel. What a marketer can do is narrower: state the status and teach the biology.
Two labels come up a lot in supplier pitches. The first is “361 product.” A product qualifies for 361 only if it meets all four criteria in 21 CFR 1271.10(a). One of them looks at advertising. The definitions in 21 CFR 1271.3 also list secreted or extracted human products among the things that are not HCT/Ps. Our explainer on the 361 and 351 lanes lays out the test.
The second label is “off-label.” Off-label means an approved or cleared product used outside its label. No exosome product has a label to step outside of. So “off-label exosome therapy” makes the status sound better than it is. The accurate word is unapproved.
What this means for your practice: Your counsel decides whether you offer exosomes. Your marketing decides only what you say, and that list is short.
Exosomes and PRP Start From Different Places
Many clinics market PRP and exosomes the same way. They should not. PRP devices are FDA cleared for handling bone graft material. Using PRP for joints, hair or skin is off-label. An exosome page has no cleared device and no approved product to describe.
Here is how the two compare.
| Comparison Point | PRP | Exosome Products |
|---|---|---|
| What it is | A blood component, not an HCT/P | Extracellular vesicles, tiny particles that cells release |
| FDA status | Devices cleared for handling bone graft material | No exosome product is FDA approved for any use |
| Use at a clinic | Joints, hair or skin use is off-label | No approved use to step outside of |
| What a page can say | The cleared use, off-label framing, no disease claims | Biology and status only |
What this means for your practice: Do not copy your PRP page layout onto exosomes. The PRP page has a cleared device behind it. The exosome page has nothing behind it but the status.
What a Clinic Can Publish About Exosomes
Education. A clinic can explain what exosomes are and state that no FDA-approved exosome product exists. That is where it stops.
Here is what an exosome education page can hold:
- What exosomes are: extracellular vesicles, tiny particles that cells release, which scientists study to learn how cells signal.
- The status sentence, word for word, near the top of the page.
- Links to the FDA’s own notices on exosome products.
- A plain note on why the page makes no treatment claims.
Here is what it cannot hold: a treatment claim, a condition list, a procedure, a price, a testimonial or a booking path. Soft words do not help. Since the FDA’s October 13, 2026 letter, “supports,” “promotes” and “may aid” are out for any exosome, cord or placental product. Our Do Use and Do Not Use list for exosome copy goes line by line.
Any health claim also needs real proof under the FTC standard for health claims. For exosomes, that proof does not exist. In our traffic light framework for regen claims, every exosome treatment claim sits in red.
Supplier copy is the other trap. Keep certificates of analysis, donor screening records and sterility tests on file, and do not promote them. A supplier white paper or viability study becomes your promotion when you post it. FDA letters in August and September 2026 cited that kind of material, along with mechanism claims and cell counts. And “FDA registered” is not a quality badge, because registration is not approval.
What this means for your practice: Biology and status. If a sentence does a third job, cut it. Our guide to building an exosome education page instead of a service page walks through each part.
Why a Consult Line Turns Education Into an Offer
A consult invite next to exosome content tells the reader your clinic provides exosomes. That turns the page into an offer for a product with no FDA approval. The compliance rules I follow treat any exosome service or booking prompt as a red line. A consult invite is a booking prompt.
A lot of exosome advice online still calls the consult line the safe call to action. For PRP, it can work, because there is a cleared device and an off-label use to talk through. For exosomes, there is no approved product to talk through. So the consult line does the selling the rest of the page avoided.
The FDA judges what a product is for by what the seller says and does around it. In its October 13, 2026 letter, the FDA looked at an IV brand’s exosome menu items and packages. It read them as intent to treat joint pain and inflammation. The words were soft. The menu was still an offer. On a clinic site, a consult button, an exosome inquiry form or a price line does the same job.
Watch for these. Each one turns an education page into an offer:
- A book, schedule or consult button on or next to the exosome content.
- A contact form that asks about exosomes.
- A price, package or membership that includes exosomes.
- A description of how the procedure is done at your clinic.
- An exosome item on a service menu or IV menu.
- A line like “ask us whether exosomes are right for you” anywhere on the page.
What this means for your practice: If a reader can get from your exosome page to an appointment, the page is an offer. Take out the path, not just the adjectives. Our post on why regen clinic marketing ends up at risk shows where that usually starts.
What About Google Ads for Exosomes?
Google Ads does not accept exosome therapy advertising. Google’s ban on speculative and experimental treatments catches it. The policy page does not name exosomes, but the ban still applies. The compliance rules I follow treat exosome ads as banned on every paid platform.
Some regen services have a narrow educational path in Google Ads. Our guide to Google Ads for regen practices covers where that path applies. Exosomes are not one of them.
What this means for your practice: Do not build a paid plan around exosome content. Keep exosomes on an organic education page, and plan paid media around other services.
Picture a Practice Rewriting Its Exosome Page
Picture a practice with an exosome page built from a supplier’s handout. The page says the product supports recovery from joint injury. It lists conditions by name. A button at the bottom says to book a consult.
The Challenge: The owner wants to keep the page. The office manager wants to know which words to swap.
The Approach: The team starts with the product, not the words. The product is not FDA approved, so the page cannot sell it. The condition list, the soft verbs and the button come out. So does the paragraph on how the procedure is done at the practice.
The Compliance Check: What stays is biology and status. That means what exosomes are, the status sentence and links to the FDA’s notices. Supplier documents go into a file, not onto the page. Whether to offer the product at all goes to counsel, in writing.
What Changed: The page stopped selling. It became an education page with no path to an appointment. The offer question sat with counsel.
Note: This scenario is illustrative and does not reference any specific Regen Portal client.
Frequently Asked Questions
Is There Any FDA Exosome Approval Right Now?
No. No exosome product is FDA approved for any use, and the FDA treats exosomes used to treat disease as drugs and biological products. The FDA has said so since its 2019 public safety notification.
Why Does the FDA Treat Exosomes as Drugs?
When an exosome product is meant to treat a disease, it is a drug under the FD&C Act. It is also a biological product under the Public Health Service Act. Both need premarket approval before the product can be sold as a treatment. No exosome product has that approval.
Is It Illegal for a Clinic to Offer Exosome Services?
That is a legal question for your counsel, not your marketing team. What is settled is the product’s status. No exosome product is FDA approved, so the product itself is the core exposure, not only the wording. A clinic’s content stays at biology and status.
What Can a Clinic Publish About Exosomes?
Biology and status. A clinic can explain that exosomes are extracellular vesicles that cells release. It can state that no FDA-approved exosome product exists. It can link to the FDA’s own notices. It cannot add claims, conditions, a procedure description, prices, testimonials or a booking path.
Why Is a Consult Invite a Problem on an Exosome Page?
A consult invite tells the reader the clinic provides exosomes. That makes the page an offer for an unapproved product. Soft wording does not fix it. The FDA’s October 2026 letter read an IV brand’s exosome menu as intent to treat.
Can a Clinic Call Exosome Use Off-Label?
No. Off-label means an approved or cleared product used outside its label. No exosome product is approved, so there is no label to step outside of. The accurate word is unapproved.
Can a Clinic Run Google Ads for Exosomes?
No. Google Ads does not accept exosome therapy advertising. It falls under Google’s ban on speculative and experimental treatments.
Does State Law Change Any of This?
No state law changes an exosome product’s federal status. Some states require a notice, word for word, in stem cell ads. A few of those laws reach further. Ask counsel whether your state’s law covers exosomes. Our guide to state stem cell and exosome rules covers each state.
Key Takeaways
- No exosome product is FDA approved for any use, and the FDA treats exosomes used to treat disease as drugs and biological products.
- The product’s status is the core exposure, not only the wording.
- What a clinic can publish is biology and status, with links to the FDA’s notices.
- A consult invite, booking button, form or price next to exosome content turns education into an offer.
- Off-label is the wrong word for exosomes. The accurate word is unapproved.
- Google Ads does not accept exosome therapy advertising.
- Keep supplier documents on file. Do not promote them.
- Whether to offer exosomes at all is a decision for your counsel.
Let’s Talk Strategy
If you have been told to either market exosomes hard or avoid the topic, there is a third option. Publish education: the biology, the status and the FDA’s own sources, with no offer attached. That is a page you can stand behind.
Regen Portal builds marketing strategies for regenerative medicine clinics that account for these compliance realities from the first piece of content forward.
For a conversation about your specific situation, reach out at hello@regenportal.com.
For deeper dives on compliance and marketing strategy, subscribe to the Regen Portal YouTube channel: https://www.youtube.com/@oatellez
The gap between what is true and what is sayable is where most exosome pages get into trouble. A marketing compliance review maps that gap for your specific claims.
About Regen Portal
Regen Portal is a marketing and consulting company built for the regenerative medicine industry. We handle practice consulting, marketing compliance, search engine optimization, content creation, social media management, paid advertising, website development, branding, and AI and ops consulting for clinics, manufacturers, distributors, and independent providers. For more on me and how we work, visit Regen Portal and contact us.
About the Author
Oscar Tellez is the founder of Regen Portal, a marketing and consulting company built for the regenerative medicine industry. He has been in this industry since 2015. He started in medical sales and has worked with PRP since 2016. He has reached hundreds of practices and over 200 doctors through sales, teaching and marketing. He holds a B.S. in Exercise Science and Health Promotion from Florida Atlantic University.
